Thalia Monro-Somerville1, Malcolm Sim, James Ruddy, Mark Vilas, Michael A Gillies. 1. 1Department of Anaesthesia, Critical Care and Pain Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.2Department of Anaesthesia, Critical Care and Pain Medicine, Queen Elizabeth University Hospital, Glasgow, United Kingdom.3Department of Anaesthesia, Critical Care and Pain Medicine, Monklands General Hospital, Airdrie, United Kingdom.
Abstract
OBJECTIVE: High-flow nasal cannulae are used in adults with or at risk of acute respiratory failure. We conducted a systematic review and meta-analysis to evaluate the evidence for their use in this setting. DATA SOURCES: Ovid Medline, Embase, and Cochrane Database of Systematic Reviews. STUDY SELECTION: Databases were searched for randomized controlled trials comparing administration of high-flow nasal cannulae with usual care (i.e., conventional oxygen therapy or noninvasive ventilation) in adults with respiratory failure. The primary outcome was hospital mortality; the rate of intubation and assessment of delirium and comfort were secondary outcomes. DATA EXTRACTION: One hundred forty-seven nonduplicate citations were screened, 32 underwent full screening and data extraction, and 14 trials were eligible for inclusion in the review. Nine trials were used in the meta-analysis, including a total of 2,507 subjects. DATA SYNTHESIS: When high-flow nasal cannulae were compared with usual care, there was no difference in mortality (high-flow nasal cannulae, 60/1,006 [6%] vs usual care, 90/1,106 [8.1%]) (n = 2,112; p = 0.29; I, 25%; fixed effect model: odds ratio, 0.83; 95% CI, 0.58-1.17) or rate of intubation (high-flow nasal cannulae, 119/1,207 [9.9%] vs usual care, 204/1,300 [15.7%]) (n = 2,507; p = 0.08; I, 53%; random effect model: odds ratio, 0.63; 95% CI, 0.37-1.06). A qualitative analysis of 13 studies on tolerability and comfort suggested that high-flow nasal cannulae are associated with improved patient comfort and dyspnea scores. Trial sequential analyses on primary and secondary outcomes suggested that required information size was not reached. CONCLUSIONS: No difference in mortality or intubation was detected in patients with acute respiratory failure treated with high-flow nasal cannulae compared with usual care. High-flow nasal cannulae seem well tolerated by patients. Further large randomized controlled trials are required to evaluate their utility in this setting.
OBJECTIVE: High-flow nasal cannulae are used in adults with or at risk of acute respiratory failure. We conducted a systematic review and meta-analysis to evaluate the evidence for their use in this setting. DATA SOURCES: Ovid Medline, Embase, and Cochrane Database of Systematic Reviews. STUDY SELECTION: Databases were searched for randomized controlled trials comparing administration of high-flow nasal cannulae with usual care (i.e., conventional oxygen therapy or noninvasive ventilation) in adults with respiratory failure. The primary outcome was hospital mortality; the rate of intubation and assessment of delirium and comfort were secondary outcomes. DATA EXTRACTION: One hundred forty-seven nonduplicate citations were screened, 32 underwent full screening and data extraction, and 14 trials were eligible for inclusion in the review. Nine trials were used in the meta-analysis, including a total of 2,507 subjects. DATA SYNTHESIS: When high-flow nasal cannulae were compared with usual care, there was no difference in mortality (high-flow nasal cannulae, 60/1,006 [6%] vs usual care, 90/1,106 [8.1%]) (n = 2,112; p = 0.29; I, 25%; fixed effect model: odds ratio, 0.83; 95% CI, 0.58-1.17) or rate of intubation (high-flow nasal cannulae, 119/1,207 [9.9%] vs usual care, 204/1,300 [15.7%]) (n = 2,507; p = 0.08; I, 53%; random effect model: odds ratio, 0.63; 95% CI, 0.37-1.06). A qualitative analysis of 13 studies on tolerability and comfort suggested that high-flow nasal cannulae are associated with improved patient comfort and dyspnea scores. Trial sequential analyses on primary and secondary outcomes suggested that required information size was not reached. CONCLUSIONS: No difference in mortality or intubation was detected in patients with acute respiratory failure treated with high-flow nasal cannulae compared with usual care. High-flow nasal cannulae seem well tolerated by patients. Further large randomized controlled trials are required to evaluate their utility in this setting.
Authors: Mihaela S Stefan; Patrick Eckert; Bogdan Tiru; Jennifer Friderici; Peter K Lindenauer; Jay S Steingrub Journal: Hosp Pract (1995) Date: 2018-02-15
Authors: Anders Perner; Andrew Rhodes; Bala Venkatesh; Derek C Angus; Ignacio Martin-Loeches; Jean-Charles Preiser; Jean-Louis Vincent; John Marshall; Konrad Reinhart; Michael Joannidis; Steven M Opal Journal: Intensive Care Med Date: 2017-01-27 Impact factor: 17.440
Authors: Amanda Corley; Claire M Rickard; Leanne M Aitken; Amy Johnston; Adrian Barnett; John F Fraser; Sharon R Lewis; Andrew F Smith Journal: Cochrane Database Syst Rev Date: 2017-05-30
Authors: Arianne K Baldomero; Anne C Melzer; Nancy Greer; Brittany N Majeski; Roderick MacDonald; Eric J Linskens; Timothy J Wilt Journal: Ann Intern Med Date: 2021-04-27 Impact factor: 25.391
Authors: Murdoch Leeies; Eric Flynn; Alexis F Turgeon; Bojan Paunovic; Hal Loewen; Rasheda Rabbani; Ahmed M Abou-Setta; Niall D Ferguson; Ryan Zarychanski Journal: Syst Rev Date: 2017-10-16